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Cancer is a leading cause of death in developed countries and second cause in developing countries.
Herein we are reporting the synthesis of novel bisbenzimidazole derivatives and their anticancer proper-
ties. Among the newly synthesized bisbenzimidazoles, 3-(4-ﬂurophenylsulfonyl)-1,7-dimethyl-2-propyl-
1H,3H-2,5-bibenzo[d]imidazole (FDPB) presented as a potent antiproliferative agent against HeLa,
HCT116 and A549 cells with selectivity over normal Vero cells (IC50 >50 lM). Additionally, we evaluated
the efﬁcacy of lead compound against Ehrlich ascites tumor (EAT) bearing mice for its antitumor and
antiangiogenic properties. Our lead compound signiﬁcantly reduced the cell viability, body weight,
ascites volume and downregulated the formation of neovasculature and production of Vascular
Endothelial Growth Factor (VEGF).
 2015 Elsevier Ltd. All rights reserved.9Cancer is a most ravaging disease threatening globally with a
leading mortally rate in developed countries.1 Various types of can-
cers have been identiﬁed which affects different organs and they
are broadly grouped under the category of carcinoma, sarcoma,
lymphoma or leukemia based on the type of tissue origin.2,3 Most
common striking features of all types of cancer is uncontrolled cell
proliferation, antiapoptosis, enhanced angiogenesis, genomic
instability and metastasis.4 The broad range of devastating charac-
teristics of the cancer makes it a very good therapeutic target for
designing the small molecules. In cancer drug discovery
programme, researchers have contributed many novel synthetic
compounds as anticancer drugs.
Benzimidazoles are the most prominent heterocycles with
diverse biological functions.5–7 Multiple previous reports have sug-
gested that benzimidazoles to be very good cytotoxic agents
against different types of cancer cell lines.8 Recently bisbenzimida-
zole conjugates have been reported to target mitochondria in can-
cer cells and induce their antiproliferative activity by caspasedependent apoptosis. In addition, bisbenzimidazoles bind to
minor groove of the DNA to instigate its anti-proliferative effect
and many DNA minor groove binders have entered clinical trials
in cancer treatment.10,11 Furthermore, bisbenzimidazoles possess
topoisomerase-112 and serine protease inhibition,13 antiviral,14
antileishmanial,15 and several other biological properties.16 In con-
tinuation of our effort in designing small molecules as anticancer
agents, bisbenzimidazoles drawn our interest to synthesize the
novel bisbenzimidazoles and evaluate their anticancer activity
both in vitro and in vivo.17–24 Among the newly synthesized com-
pounds, we selected the most potent cytotoxic compound against
HeLa (Cervical cancer), HCT116 (Colon cancer), A549 (Lung cancer)
and evaluated for its in vivo antitumor and antiangiogenic proper-
ties using Ehrlich ascites tumor (EAT) bearing mice.
A mixture of methyl 3,4-diamino-5-methyl benzoate 1, buta-
noic acid and polyphosphoric acid (PPA) were irradiated in a
microwave ﬂask at 150 C for 10 min to get methyl 4-methyl-2-
propyl-1H-benzo[d]imidazole-6-carboxylate 2. The key intermedi-
ate 1,70-dimethyl-20-propyl-1H,30H-2,50-bibenzo[d]imidazole 3
was obtained by the reaction of 2 with N-methyl-o-phenylenedi-
amine using PPA at 150 C for 12 h.25 Finally, key intermediate 3
was subjected to undergo N-sulfonation with various sulfonyl
chlorides 4 to get respective 1,70-dimethyl-30-(arylsulfonyl)-20-
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tures of all the synthesised compounds were conﬁrmed by spectral
and micro analytical analysis. All ﬁnal compounds showed charac-
teristic triplet between 0.8 and 1.1 d for methyl protons, triplet
around 3.1 d, sextet around 1.9 d for methylene protons, singlet
at 2.0 d for aryl methyl protons and singlet at 3.9 d for N-methyl
protons. The structures and yields of the synthesised compounds
are given in Table 1.
FDPB induces its cytotoxic effect in time and dose dependent man-
ner in HeLa cells: We investigated the anti-proliferative effect of
newly synthesized bisbenzimidazoles 5a–j against the panel of cell
lines including HeLa, HCT116 and A549 cells using MTT assay as
described previously and IC50 values are tabulated in
Table 1.18,26,27 We found bisbenzimidazoles 5d and FDPB having
p-methoxy- and p-ﬂurosulfonyl groups exhibited signiﬁcant cyto-
toxicity towards HeLa and HCT116 cells with the IC50 values rang-
ing from 16.7 lM to 19.9 lM. Further, bisbenzimidazoles 5b–c
bearing tolyl and mesityl sulfonyl groups displayed notable anti-
cancer activity with IC50 values ranging from 20.1 lM to 41.6 lM
against HeLa and HCT116 cells. Compounds 5h–j substituted with
2,5-dichlro-, 2-chloro and 2-bromophenylsulfonyl groups were
found to be inactive against HeLa cells. On the other hand, most
of the new bisbenzimidazole derivatives displayed least antiprolif-
erative activity against A549 and monkey kidney epithelial (Vero)
cells up to 50 lM. Thus compounds with inductively electron
releasing methyl groups are good inhibitors over unsubstitutedFigure 1. (A) Schematic representation of synthesis of bisbenzimidazoles: (i) butanoic
phenylenediamine, PPA, 150 C, 12 h. (iii) RSO2Cl 4, TBAB, 50% NaOH, C6H6, 5–6 h. (B) FD
Flow cytometric analysis indicates the arrest of HeLa cells in SubG1 phase in the time dcounterparts. Also, strong electron releasing and withdrawing sub-
stituents increased the activity. Notably, the activity decreases
with decrease in electro negativity of halogen at para position of
sulfonyl motif. Finally, halogen substitution at ortho position of
arylsulfonyls is ineffective. Despite the fact that all compounds
are less potent than standard sorafenib, the structure activity rela-
tionship proﬁles is very interesting. Furthermore, we identiﬁed
FDPB as potent cytotoxic agent and tested on HeLa cells at indi-
cated dose and time points and found the substantial decrease in
viable cells (Fig. 1B). The lead compound FDPB is taken for further
in vivo studies.
FDPB interferes with cell cycle and arrest HeLa cells in SubG1
phase: Formation of hypodiploid cells is a hallmark event in cells
undergoing apoptosis which can be detected using propidium
iodide staining.28 We evaluated whether FDPB can effect cell cycle
distribution as described earlier.29 We found the built up of cells in
subG1 phase in the time dependent manner (Fig. 1C). The results
conﬁrmed the cytotoxic effect of FDPB.
FDPB signiﬁcantly decrease ascites volume, body weight and cell
viability: We further analysed the effect of FDPB on body weight
and ascites volume in the tumor of drug treated and control mice
as described earlier.21 We observed the signiﬁcant decrease in
the body weight after the administration of FDPB (Fig. 2A and
B). Based on this observation, we quantiﬁed the ascites volume
and results conﬁrmed the decrease of ascites ﬂuid (Fig. 2C). In
addition, results of trypan blue assay displayed the substantialacid, polyphosphoric acid (PPA), MW irradiation 150 C, 10 min. (ii) N-Methyl-o-
PB suppresses proliferation of HeLa cells in time and dose dependent manner. (C)
ependent manner.
Table 1
Structures, yield and cytotoxicity (lM ± SD) data of the bisbenzimidazole derivatives 5a–j
Sl no R (4, 5) 5 % yielda HeLa (lM) HCT116 (lM) A549 (lM) Vero (lM)
1 C6H5 5a 56 23.8 ± 1.6 >50 >50 >50
2 4-MeC6H4 5b 83 20.1 ± 3.1 41.6 ± 4.9 >50 >50
3 2,4,6-Me3C6H2 5c 90 21 ± 3.9 29.9 ± 5.9 >50 >50
4 4-MeOC6H4 5d 72 18.3 ± 2.1 19.1 ± 10.1 34.7 ± 6.3 >50
5 4-FC6H4 5e (FDPB) 65 16.7 ± 5.8 19.9 ± 8.2 32.2 ± 7.5 >50
6 4-ClC6H4 5f 67 21.4 ± 5.4 36.8 ± 5.4 >50 >50
7 4-BrC6H4 5g 84 24.7 ± 5.7 49.3 ± 6.5 35.1 ± 9.1 >50
8 2,5-Cl2C6H3 5h 87 >50 NT NT NT
9 2-ClC6H4 5i 62 >50 NT NT NT
10 2-BrC6H4 5j 68 >50 NT NT NT
NT—not tested.
a Yield corresponds to the last step of the synthesis.
Figure 2. Evaluation of antitumor activity of compound FDPB on EAT bearing mice. (A) Photographs of FDPB treated, normal and EAT bearing mice. (B) FDPB decreases the
body weight of tumor bearing mice compared to tumor bearing control and Cisplatin administered tumor bearing mice. (C) FDPB decreases the ascites ﬂuid volume in the EAT
mice. (D) Percentage of viable cell count signiﬁcantly reduced in FDPB treated mice.
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This concludes that our lead molecule possess very good anticancer
property.
FDPB suppresses angiogenesis in EAT bearing mice: Angiogenesis
is associated with tumor expansion by uncontrolled cell prolifera-
tion and metastasis.30 Therefore inhibition of angiogenesis is a
direct measure of increased prognosis. We evaluated whether
FDPB can downregulate neovasculature and micro vessel density
(MVD) in the peritoneal cavity of EAT bearing mice. Figure 3A
clearly shows that FDPB notably suppress the peritoneal angiogen-
esis. Additionally, quantiﬁcation of MVD in the H & E stained peri-
toneum tissue displayed signiﬁcant reduction in the number of
micro vessels (Fig. 3B). 8 ± 2 vessels/high power ﬁeld were
observed in FDPB treated mice compared with 54 ± 6 vessels/
High power ﬁeld in control mice.
FDPB downregulates the VEGF in Ehrlich ascites tumor: Based on
the predominant suppression of peritoneal angiogenesis and
MVD, the effect of FDPB on the local production of VEGF in the
peritoneal cavities of EAT bearing mice was investigated using
ELISA based method.31 The levels of VEGF substantially decreased
in the lavage ﬂuid to 225 ± 4 ng in FDPB treated mice (Fig. 3C), In
contrast, the levels of VEGF were found to be 2412 ± 10 ng in the
control mice conﬁrming the anti-angiogenic role of FDPB.
FDPB induces apoptosis in Ehrlich ascites tumor cells: Cellular
morphological changes, shrinkage and fragmentation of genomic
DNA are the hallmark events in the cell undergoing apoptosis.32Figure 3. FDPB inhibits neovasculature in EAT bearing mice. (A) FDPB suppress
peritoneal angiogenesis in EAT bearing mice. (B) H & E staining of peritoneum of
FDPB treated mice displayed the substantial decrease of MVD. (C) Proﬁling of VEGF
in the lavage ﬂuid collected from EAT bearing FDPB treated and control mice. (D)
FDPB induces apoptosis in Ehrlich ascites tumor cells and it is demonstrated by DNA
fragmentation in FDPB treated mice (D—DNA ladder; C—Tumor control). (E)
Morphological changes in cells and formation of apoptotic bodies in EAT cells of
FDPB treated mice.Inhibition of peritoneal angiogenesis encouraged us to investigate
whether FDPB can induce its anti-proliferative effect by promoting
apoptosis in Ehrlich ascites cells. We performed DNA fragmenta-
tion assay to detect the intactness of the DNA in cells treated with
our lead compound. The results obtained clearly demonstrate the
extensive degradation of genomic DNA and concluding that FDPB
induces apoptosis (Fig. 3D). Furthermore, morphological changes
of the cells treated with our lead compound was evaluated by
Giemsa staining. Microscopic observation of cells stained with
Giemsa displayed cell shrinkage, formation of small blebs and
apoptotic bodies (Fig. 3E).
In conclusion, an ideal anti-cancer drug should inhibit the pro-
liferation of cancer cells, prevent metastasis, enhance apoptosis
and suppress angiogenesis in tumors.33,34 Designing and synthesis
of novel small molecules that can target cancer cells speciﬁcally
and inhibiting their proliferation by disrupting the multiple sur-
vival signals is a prime challenge in cancer drug discovery. In con-
tinuation of our effort to synthesize new anti-cancer agents and
considering the contribution of benzimidazole nucleus in the
development of various drugs, we herein report the synthesis,
characterization, anti-proliferative and anti-angiogenic activity of
novel bisbenzimidazole derivatives. Newly synthesized com-
pounds were evaluated for their cytotoxic efﬁcacy against HeLa,
HCT116 and A549 cells and lead compound was carried forward
for the evaluation of its in vivo antitumor activity. In addition,
the lead compound did not display cytotoxicity towards non-
diseased (Vero) cells. Linlin and colleagues have demonstrated that
bisbenzimidazole derivatives induce cytotoxicity in cancer cells
through both death receptor and mitochondria-mediated apop-
totic pathways.9 Therefore, we are concluding that, our lead com-
pound possibly induce its antiproliferative effect on cancer cells
by activating caspases which are known to induce activation of
caspase-activated DNases (CAD). The activation of CAD proteins
leads to the degradation of genomic DNA into nucleotide oligomers
thereby inducing apoptosis of cancer cells. In summary, FDPB
proved to be an efﬁcient anticancer agent with a therapeutic
potential to combat cancer.
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